Summary & Overview
CPT 82525: Copper Quantification for Liver Disease Evaluation
CPT code 82525 represents a laboratory assay for quantifying copper in a patient specimen, used primarily to investigate hepatocellular degeneration and obstructive liver disease. This test has clinical importance for diagnosing and monitoring disorders of copper metabolism and liver dysfunction; its accurate measurement can influence diagnosis and downstream clinical management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national-level context for the code, including clinical indications, typical service settings, and the type of laboratory service represented. The publication outlines expected benchmarks where available, summarizes common billing considerations, and situates the test within clinical workflows for liver-related evaluations.
This summary provides clinicians, billing professionals, and policy analysts with a concise overview of the purpose and setting for CPT code 82525, what stakeholders commonly consider when processing claims for copper testing, and what to expect in terms of service categorization and clinical rationale. Data not available in the input: specific payer coverage policies, reimbursement rates, associated ICD-10 codes, and procedure modifiers.
Billing Code Overview
CPT code 82525 describes a quantitative measurement of copper in a patient specimen. The test is performed by a laboratory analyst to assess copper concentration and is commonly used when evaluating hepatocellular degeneration and obstructive liver disease.
Service type: Clinical laboratory test — biochemical assay
Typical site of service: Clinical laboratory or hospital laboratory (inpatient or outpatient specimen analysis)
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient presents to the outpatient hepatology clinic with progressive jaundice, unexplained fatigue, and elevated liver enzymes on prior basic metabolic testing. The ordering hepatologist collects a serum specimen to measure copper concentration to evaluate for hepatocellular degeneration, Wilson disease, or cholestatic/obstructive liver disease. The specimen is sent to the clinical laboratory where a chemistry or trace elements analyst performs quantitative copper analysis (serum or plasma) using atomic absorption spectrometry or inductively coupled plasma mass spectrometry. Results are reviewed by the lab director and reported to the ordering provider; abnormal results prompt correlation with ceruloplasmin, 24-hour urinary copper, hepatic imaging, and possible liver biopsy. Typical site of service is an outpatient hospital laboratory, independent reference laboratory, or hospital inpatient laboratory when performed for admitted patients.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When a physician provides interpretation or professional oversight distinct from the technical lab processing |
TC | Technical component |